

OncoBEAM EGFR Kit v2 (RUO)

Highly sensitive liquid biopsy for the detection of EGFR mutations




Go beyond biopsy with blood

Reliable detection of EGFR mutations in plasma from metastatic non-small cell lung cancer (NSCLC) patients

- Highly sensitive BEAMing digital PCR technology combining digital PCR and flow cytometry
- Detection of 36 EGFR mutations based on cell-free tumour DNA, including T790M and C797S
- A more rapid and minimally invasive assessment of EGFR mutations, as compared to tissue biopsy¹


Quick. Whenever. Just blood.

EGFR mutation frequency in non-small cell lung cancer



- Assessment of the EGFR mutation status is required to select NSCLC patients eligible for EGFR tyrosine kinase inhibitor (TKI) therapy.^{2,3}
- 40 55% of acquired resistance to first- and secondgeneration EGFR TKI-targeted therapies is based on T790M mutation.⁴ Therefore, reliable assessment of T790M is required before applying third-generation EGFR TKI therapy.

Mechanisms of resistance to EGFR TKIs



- Clinical studies have demonstrated high concordance for T790M-positive plasma samples compared with T790Mpositive tissue-based results.⁵ In plasma-negative samples, a tissue biopsy is recommended if feasible.⁵
- EGFR C797S mutation is associated with resistance to osimertinib in EGFR T790M-positive patients.⁶

OncoBEAM EGFR Kit v2 (RUO*) 36 EGFR mutations	Type of mutation	EGFR exon	Mutations
	Sensitising	18	G719A, G719S, G719C
		19	ΔΚ745, ΔΕ746, ΔL747
		21	L858R, L861Q
	Resistance	20	T790M, C797S

*For research use only. Any in vitro diagnostic purpose has not been established by the manufacturer. Not available in the USA.

- [1] Sacher AG et al. (2016): Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. 2(8):1014–1022.
- [2] NCCN (2017): Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 6.
- [3] Novello S et al. (2016): Metastatic Non-Small-Cell Lung Cancer. ESMO Clinical Practice Guidelines. Ann Oncol. 27(suppl 5):v1–v27.
- [4] Westover D et al. (2018): Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol; 29 (suppl 1):i10 i19.
- [5] Oxnard GR et al. (2016): Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-smallcell lung cancer. J Clin Oncol. 34(28): 3375 – 3382.
- [6] Thress KS et al. (2015): Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 21(6):560 – 562.

Distributor: Sysmex Europe GmbH Bornbarch 1, 22848 Norderstedt, Germany · Phone +49 40 52726-0 · Fax +49 40 52726-100 · oncology@sysmex-europe.com · www.sysmex-europe.com Manufacturer: Sysmex Inostics GmbH Falkenried 88, 20251 Hamburg, Germany · Phone +49 40 325907-0 · Fax +49 040 325907-6699 · info@sysmex-inostics.com · www.sysmex-inostics.com Sysmex Corporation 1-5-1 Wakinohama-Kaigandori, Chuo-ku, Kobe 651-0073, Japan · Phone +81 78 265-0500 · Fax +81 78 265-0524 · www.sysmex.co.jp You will find your local Sysmex representative's address under www.sysmex-europe.com/contacts